Engineering Saccharomyces cerevisiae for medical applications

Microbial Cell Factories, Journal Year: 2025, Volume and Issue: 24(1)

Published: Jan. 9, 2025

Abstract Background During the last decades, advancements in synthetic biology opened doors for a profusion of cost-effective, fast, and ecologically friendly medical applications priorly unimaginable. Following trend, genetic engineering baker’s yeast, Saccharomyces cerevisiae , propelled its status from an instrumental ally food industry to therapy prophylaxis aid. Main text In this review, we scrutinize main engineered S. field focusing on use as cell factory pharmaceuticals vaccines, biosensor diagnostic biomimetic assays, live biotherapeutic product smart situ treatment intestinal ailments. An extensive view these fields' academic commercial developments well hindrances is presented. Conclusion Although still faces challenges, development yeast-based often considered success story. The rapid advances strongly support case future where yeasts play important role medicine.

Language: Английский

---

Enabling technologies for in situ biomanufacturing using probiotic yeast

Advanced Drug Delivery Reviews, Journal Year: 2025, Volume and Issue: unknown, P. 115605 - 115605

Published: May 1, 2025

Saccharomyces boulardii (Sb) is a Generally Regarded As Safe (GRAS) probiotic yeast currently used to alleviate symptoms from various gastrointestinal diseases. Sb promising platform for and biotherapeutic engineering as it the only eukaryote carries with unique set of advantages compared bacterial strains, including resistance phage, high protein secretion abilities, intrinsic antibiotics. While engineered has not been studied extensively its close relative cerevisiae (Sc), many genetic tools developed Sc have also shown promise in Sb. In this review, we address recent research develop engineering, colonization modulation, biomarker sensing, drug production Ongoing efforts, especially those that overcome gut-specific challenges performance, are highlighted they advance chassis scalable treating

Language: Английский

---

Typing of clinical and reference strains of Saccharomyces cerevisiae using pulsed-field gel electrophoresis and MALDI-TOF MS

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: May 16, 2025

In recent years matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) has emerged as a rapid and reliable tool for microbial identification diagnosis. However, its use molecular typing of S. cerevisiae been investigated in limited number studies, mainly based on brewing strains. The purpose the study was to compare results gold standard pulsed-field gel electrophoresis (PFGE) with MALDI-TOF MS subset clinical reference comprised 50 isolates, collected from single patients hospitalized Central Clinical Hospital Medical University Warsaw between 2014 2016. Furthermore eight strains i.e. three probiotic, four baker one winery strains, were included. Strain performed using PFGE MS. split sample into six clusters two unique profiles. Whereas produced five clusters. Overall, congruent all (49/50; 97%) but isolates. both analyses, probiotic unlike baker's clustered only Although had higher resolution capacity than MS, methods allowed clear discrimination clinically relevant (clinical & probiotic) irrelevant (baker's winery) This is first time that proven useful epidemiological studies cerevisiae.

Language: Английский

---

Effect of Mutant and Engineered High-Acetate-Producing Saccharomyces cerevisiae var. boulardii Strains in Dextran Sodium Sulphate-Induced Colitis

Nutrients, Journal Year: 2024, Volume and Issue: 16(16), P. 2668 - 2668

Published: Aug. 13, 2024

Acetate-producing Saccharomyces cerevisiae var. boulardii strains could exert improved effects on ulcerative colitis, which here, was preclinically evaluated in an acute dextran sodium sulphate induced model of colitis. Nine-week-old female mice were divided into 12 groups, receiving either drinking water or 2.75% for 7 days, combined with a daily gavage various treatments different levels acetate accumulation: sham control (phosphate buffered saline, no acetate), non-probiotic (Baker’s yeast, probiotic (Enterol®, transient and additionally several respectively no, high, extra-high accumulation. Disease activity monitored daily, feces samples collected at timepoints. On day 14, the sacrificed, upon blood colonic tissue analysis. inflamed lower when treated high-acetate-producing strain compared to controls. The non-acetate-producing showed higher disease acetate-producing strains. Accordingly, histologic inflammation observed non- transient-acetate-producing control, whereas this increase not high- extra-high-acetate-producing induction inflammation. These anti-inflammatory findings confirmed by transcriptomic analysis differentially expressed genes. Moreover, only highest production superior maintaining stable gut microbial alpha-diversity support new possibilities acetate-mediated management inflammatory bowel administrating cerevisae

Language: Английский

---